NCT06771193Recruiting
Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy
RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy
Source: ClinicalTrials.gov · Last updated 20 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 7 Jan 2025
- Start date
- 17 Dec 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- MSD Italia S.r.l.
- Diseases
- Cervical cancer
- NCT number
- NCT06771193
What you commit to
- Study type: Observational
- Planned participants: 200
- From 17 Dec 2024 to the primary completion date, Dec 2025
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs
Other illness
- Patients participating in a pharmacological clinical trial for the treatment of advanced disease
Other
- Patients who participated in a clinical trial
Who the study is looking for
- Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF)
- Age ≥18 years
- Diagnosis of a cervical cancer
- Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease
- Any treatment received between January 2018 and December 2021 for advanced disease
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Irccs Centro Di Riferimento Oncologico (CRO) Coordinator of this site? Confirm its status | Aviano | Italy | Recruiting |
| Oncologia Medica Policlinico Sant'Orsola - Malpighi Coordinator of this site? Confirm its status | Bologna | Italy | Recruiting |
| Ginecologia ed Ostetricia A.O. Cannizzaro Coordinator of this site? Confirm its status | Catania | Italy | Recruiting |
| Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino Coordinator of this site? Confirm its status | Genova | Italy | Recruiting |
| UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima Coordinator of this site? Confirm its status | Mestre | Italy | Not yet recruiting |
| Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
| Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
| Oncologia A.O.U. di Modena - Policlinico Coordinator of this site? Confirm its status | Modena | Italy | Recruiting |
| UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
| U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
| U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.